Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2007-005306-49-DK
EUCTR2007-005306-49-DKActive, not recruitingNot Applicable

A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia

Department of Haematology, Herlev Hospital, University of Copenhagen0 sites80 target enrollmentStarted: July 10, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
80
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •11. Male or female patient > 18 years of age and
  • •2. A confirmed diagnosis of PV (see appendix 1) and
  • •3. Biochemical evidence of active disease as defined by
  • •a) A need for phlebotomy within the last 3 months
  • •b) a leukocyte count > 10 x 109/L in the absence of infection or inflammation
  • •(normal CRP) and/or (PV/ET)
  • •c) a platelet count > 450 x 109/L in the absence of infection or inflammation
  • •(normal CRP) (PV/ET).
  • •1. Male or female patient > 18 years of age and
  • •2. A confirmed diagnosis of high risk ET (see appendix 1) and
  • •3. Biochemical evidence of active disease as defined by
  • •a) a platelet count > 450 x 109/L in the absence of infection or inflammation
  • •(normal CRP).
  • •1. Newly diagnosed or previously treated patients in chronic phase or
  • •2. Advanced phase PV or ET as defined by blasts of > 1 x 109/L in the peripheral blood and/or white cell count > 30 x 109/L or
  • •3. Resistant or refractory PV or ET as defined by a haemoglobin < 10.5gm/dl with a platelet count > 600 x 109/L on current therapy or
  • •4. Cycling platelet counts on therapy or
  • •5. Intolerant to other therapies defined by patients with PV or ET who have side effects on current therapies preventing continuation (leg ulcers on hydroxycarbamide, unacceptable fatigue etc on interferon).
  • •1. Male or female patient > 18 years of age and
  • •2. A confirmed diagnosis of primary myelofibrosis, post-polycythaemia vera myelofibrosis or
  • •post-essential thrombocythaemia myelofibrosis (12,13,55) and
  • •3. Splenomegaly as assessed clinically or by abdominal ultrasound (patients who have had splenectomy for huge splenomegaly can be included )
  • •4. Newly diagnosed or previously treated patients in chronic phase or advanced phase MF.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •1. A platelet count > 1500 x 109/L (a need for cytoreduction in platelet count)
  • •2. Patients of childbearing potential without a negative pregnancy test prior to initiation of study drug.
  • •3. Women who are breast feeding
  • •4. Males and females not using contraceptives if sexually active.
  • •It is recommended that 2 reliable forms of contraception be used simultaneously unless abstinence is the chosen method of contraception. Non-pregnant, non-breast-feeding women may be enrolled if they are considered highly unlikely to conceive. Highly unlikely to conceive is defined as (a) surgically sterilized, or (b) postmenopausal, or (c) not heterosexually active for the duration of the study, or (d) heterosexually active and willing to use 2 birth control methods. The 2 birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy, used throughout the study starting with Visit 1. A woman who is =45 years of age and has not had menses for greater than 2 years will be considered postmenopausal.
  • •5. ECOG Performance Status Score = 3
  • •6. Serum creatinine more than 2 x’s the ULN
  • •7. Total serum bilirubin more than 1.5 x’s the ULN
  • •8. Serum AST/ALT more than 3 x’s the ULN
  • •9. Interferon alpha within 1 week of day 1
  • •10. Hydroxycarbamide within 1 week of day 1
  • •11. Anagrelide within 1 week of day 1
  • •12. Valproic acid (as an anticonvulsant) within 28 days of day 1
  • •13. Any other investigational drug within 28 days of day 1
  • •14. Active HIV, HBV or HCV infection.
  • •15. Any serious concomitant disease or circumstances that could limit compliance with the study, including but not limited to the following: CTCAE grade 3-4 cardiac general & arrhythmia, or psychiatric or social conditions that may interfere with patient compliance.
  • •16. Any prior malignancy with the exception of cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or other localized malignancy that has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed to be at low risk for recurrence by his/her treating physician.
  • •17. Patient has a known allergy or hypersensitivity to vorinostat capsules.

Investigators

Sponsor
Department of Haematology, Herlev Hospital, University of Copenhagen

Similar Trials

Active, not recruiting
Not Applicable
A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia
EUCTR2007-005306-49-SEDepartment of Haematology, Herlev Hospital, University of Copenhagen60
Completed
Phase 2
A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential ThrombocythaemiaM. Vaquez-Oslermyeloproliverative diseases10018865
NL-OMON36951Vrije Universiteit Medisch Centrum5
Active, not recruiting
Phase 1
A phase II study of Vorinostat in patients with Polycythaemia Vera and Essential Thrombocythaemiapatients with polycythemia vera and essential thrombocythaemiaMedDRA version: 9.1Level: LLTClassification code 10036061Term: Polycythemia veraMedDRA version: 9.1Level: LLTClassification code 10015494Term: Essential thrombocythemia
EUCTR2007-005306-49-NLVUmc60
Active, not recruiting
Phase 1
A Phase II Study Of Vorinostat (MK-0683) In Patients With Polycythaemia Vera And Essential Thrombocythaemia - Vorinostat (MK0683)The myeloproliferative disorders (MPDs) polycythaemia vera (PV) and essential thrombocythaemia (ET) are chronic haematological malignancies associated with increased risk of thrombosis, haemorrhage and leukaemic transformation. Recently an acquired mutation in JAK 2 has been described in >95% of patients with PV and 50% with ET.
EUCTR2007-005306-49-GBHerlev Hospital
Active, not recruiting
Not Applicable
A Phase I/II Study of Vorinostat in Combination with Low Dose Ara-C for Patients with Intermediate-2 or High Risk Myelodysplastic Syndromes - GFM-VOR-2007-1
EUCTR2007-002212-26-FRGroupe Francophone des Myélodysplasies